A Buenestado1, S Grassin-Delyle1, F Guitard1, E Naline1, C Faisy1, D Israël-Biet1, E Sage1, J F Bellamy1, H Tenor1, P Devillier1. 1. Laboratory of Pulmonary Pharmacology UPRES EA220, Foch Hospital, University Versailles Saint-Quentin, Suresnes, FranceMedical Intensive Care Unit, Georges Pompidou European Hospital, Paris, FranceDepartment of Pneumology University Paris-Descartes, APHP, Georges Pompidou European Hospital, Paris, FranceDepartment of Thoracic Surgery, Foch Hospital, University Versailles Saint-Quentin, Suresnes, FranceThoracic Surgery, Val d'Or Clinic, Saint-Cloud, FranceDepartment of Biology, Nycomed, Konstanz, Germany.
Abstract
BACKGROUND AND PURPOSE: Lung macrophages are critically involved in respiratory diseases. This study assessed the effects of the PDE4 inhibitor roflumilast and its active metabolite, roflumilast N-oxide on the release of a range of chemokines (CCL2, 3, 4, CXCL1, 8, 10) and of TNF-α, from human lung macrophages, stimulated with bacterial lipopolysaccharide LPS. EXPERIMENTAL APPROACH: Lung macrophages isolated from resected human lungs were incubated with roflumilast, roflumilast N-oxide, PGE(2), the COX inhibitor indomethacin, the COX-2 inhibitor NS-398 or vehicle and stimulated with LPS (24 h). Chemokines, TNF-α, PGE(2) and 6-keto PGF(1α) were measured in culture supernatants by immunoassay. COX-2 mRNA expression was assessed with RT-qPCR. PDE activities were determined in macrophage homogenates. KEY RESULTS: Expression of PDE4 in lung macrophages was increased after incubation with LPS. Roflumilast and roflumilast N-oxide concentration-dependently reduced the LPS-stimulated release of CCL2, CCL3, CCL4, CXCL10 and TNF-α from human lung macrophages, whereas that of CXCL1 or CXCL8 was not altered. This reduction by the PDE4 inhibitors was further accentuated by exogenous PGE(2) (10 nM) but abolished in the presence of indomethacin or NS-398. Conversely, addition of PGE(2) (10 nM), in the presence of indomethacin restored inhibition by roflumilast. LPS also increased PGE(2) and 6-keto PGF(1α) release from lung macrophages which was associated with an up-regulation of COX-2 mRNA. CONCLUSIONS AND IMPLICATIONS: Roflumilast and roflumilast N-oxide reduced LPS-induced release of CCL2, 3, 4, CXCL10 and TNF-α in human lung macrophages.
BACKGROUND AND PURPOSE: Lung macrophages are critically involved in respiratory diseases. This study assessed the effects of the PDE4 inhibitor roflumilast and its active metabolite, roflumilastN-oxide on the release of a range of chemokines (CCL2, 3, 4, CXCL1, 8, 10) and of TNF-α, from human lung macrophages, stimulated with bacterial lipopolysaccharideLPS. EXPERIMENTAL APPROACH: Lung macrophages isolated from resected human lungs were incubated with roflumilast, roflumilastN-oxide, PGE(2), the COX inhibitor indomethacin, the COX-2 inhibitor NS-398 or vehicle and stimulated with LPS (24 h). Chemokines, TNF-α, PGE(2) and 6-keto PGF(1α) were measured in culture supernatants by immunoassay. COX-2 mRNA expression was assessed with RT-qPCR. PDE activities were determined in macrophage homogenates. KEY RESULTS: Expression of PDE4 in lung macrophages was increased after incubation with LPS. Roflumilast and roflumilastN-oxide concentration-dependently reduced the LPS-stimulated release of CCL2, CCL3, CCL4, CXCL10 and TNF-α from human lung macrophages, whereas that of CXCL1 or CXCL8 was not altered. This reduction by the PDE4 inhibitors was further accentuated by exogenous PGE(2) (10 nM) but abolished in the presence of indomethacin or NS-398. Conversely, addition of PGE(2) (10 nM), in the presence of indomethacin restored inhibition by roflumilast. LPS also increased PGE(2) and 6-keto PGF(1α) release from lung macrophages which was associated with an up-regulation of COX-2 mRNA. CONCLUSIONS AND IMPLICATIONS: Roflumilast and roflumilastN-oxide reduced LPS-induced release of CCL2, 3, 4, CXCL10 and TNF-α in human lung macrophages.
Authors: Tone Bryn; Milada Mahic; Jorrit M Enserink; Frank Schwede; Einar Martin Aandahl; Kjetil Taskén Journal: J Immunol Date: 2006-06-15 Impact factor: 5.422
Authors: Thomas D Bethke; Gabriele M Böhmer; Robert Hermann; Bernhard Hauns; Richard Fux; Klaus Mörike; Michael David; Dietrich Knoerzer; Wilhelm Wurst; Christoph H Gleiter Journal: J Clin Pharmacol Date: 2007-01 Impact factor: 3.126
Authors: David M Aronoff; Camila M Peres; Carlos H Serezani; Megan N Ballinger; Jennifer K Carstens; Nicole Coleman; Bethany B Moore; R Stokes Peebles; Lucia H Faccioli; Marc Peters-Golden Journal: J Immunol Date: 2007-02-01 Impact factor: 5.422
Authors: Donna M Slater; Shirley Astle; Nicola Woodcock; Joanna E Chivers; Norbert C J de Wit; Steven Thornton; Manu Vatish; Robert Newton Journal: Mol Hum Reprod Date: 2006-02-02 Impact factor: 4.025
Authors: Sharonjit K Gill; Yiwen Yao; Linda J Kay; Martin A Bewley; Helen M Marriott; Peter T Peachell Journal: Br J Pharmacol Date: 2016-09-06 Impact factor: 8.739
Authors: S Grassin-Delyle; E Naline; A Buenestado; C Faisy; J-C Alvarez; H Salvator; C Abrial; C Advenier; L Zemoura; P Devillier Journal: Br J Pharmacol Date: 2014-06 Impact factor: 8.739
Authors: Tatiana Victoni; Florence Gleonnec; Manuella Lanzetti; Hermann Tenor; Samuel Valença; Luis Cristovão Porto; Vincent Lagente; Elisabeth Boichot Journal: PLoS One Date: 2014-01-08 Impact factor: 3.240